EN DE
Watch Bactiquant AS for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bactiquant AS (BACTIQ) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Bactiquant AS stock DKK 0.29, price DKK 2.99, that is 90.3% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Industrials DK · ISIN DK0061417730

BA Bactiquant AS logo Thin data Nov 4, 2026

Bactiquant AS

BACTIQ · CO
Very expensive, weak quality

Our calculation puts a fair price 90% below what the stock costs today.

Low debt
Revenue last quarter +30% vs. a year ago.
Fair value kr 0.2890 · Strongly overvalued
Quality 39/100
Weak Growth (revenue 3y −12.4 %/yr in DKK)
Loss-making · -122.4% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 10/100 · thin data
Thin data
⚠ Dilution
Watch Bactiquant AS for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 12.67 kr 1.95 Fair Value kr 0.2890 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range kr 1.95 – kr 12.67 · fair‑value band kr 0.1870 – kr 0.3570 · the kr 2.99 price screens above the kr 0.2890 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Bactiquant AS in your weekly email

Every Wednesday you see whether Bactiquant AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BactiQuant A/S develops, produces, and provides technology for the mobile and online surveillance of bacterial contamination levels in water.

Show moreShow less

The company offers Mobile Lab, a handheld tool for pollution tracking; BQ Online 2.0 PRO, an online solution to quantify the bacteria in water systems; and a range of analysis kits to monitor water quality.

It serves various industries in the areas of aquaculture, data centers, oil and gas, water utility, industry, and pharma. The company was founded in 1999 and is based in Horsholm, Denmark.

Stock analysis

Bactiquant AS (BACTIQ) currently trades at kr 2.99, while our model-based Fair Value estimate is kr 0.2890, 90% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 0.1870 (bear) to kr 0.3570 (bull), the price of kr 2.99 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Industrials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Bactiquant AS reported revenue of 8.3M DKK in FY2025 versus 8.4M DKK in FY2021, a compound −0.1%/yr. Reported net income was −13.8M DKK in FY2025.

Key figures

Market cap 112M DKK (≈ $16.8M) Micro · P/S ratio 9.76 · EPS (TTM) kr −0.3400 · Net margin −122% · Return on equity −114% · Return on assets (EBIT) −56.8% (5-year average) · Operating margin −83.2% · Revenue (TTM) 9.5M DKK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 46% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Industrials peers we cover trades at 3% fair-value upside, at −90%, BACTIQ screens richer than that median.

Fair Value models

Bear kr 0.1870 Fair Value kr 0.2890 Bull kr 0.3570
Price kr 2.99 · Downside -90.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 0.2200 kr 0.3400 kr 0.4200 55
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.2200 kr 0.3400 kr 0.4200 55

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 78
Does it invest with discipline instead of growing at any price?
Low Volatility 47
How calm the share price moves, does not count
Price momentum 51
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 64
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+15.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−23.6% (2020) → −150.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BACTIQ screens overvalued: fair value 90% below the price. Compare with Veralto Corporation →

Compare Bactiquant AS with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pollution & Treatment Controls · 86 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −90.3% · Bottom 25%
Profitability
Return on assets −49.3% · Bottom 25%
Net margin (12 months) −122.4% · Bottom 25%
Operating margin (12 months) −83.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 29.5% · Top 25%
Balance sheet
Debt / equity 0.39× · Highest 25%

Valuation Multiplesvs Pollution & Treatment Controls median · lower = cheaper

P/B 6.50× · Priciest 25%
P/S (12 months) 11.77× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 12
FUTURE (revenue growth)100 · sector 22
PAST (return on equity)0 · sector 20
HEALTH (low debt)80 · sector 95
DIVIDEND (yield)0 · sector 37

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pollution & Treatment Controls stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
China Conch Venture Holdings 0586 HK$7.83 HK$23.49 +200% vs BACTIQ
Jingjin Equipment Inc 603279 ¥13.57 ¥21.71 +60% vs BACTIQ
Zurn Elkay Water Solutions Corporation ZWS $43.47 $48.24 +11% vs BACTIQ
Mega Union Technology Inc 6944 608.00 TWD 663.94 TWD +9% vs BACTIQ
Zhongyuan Environmental Protection Co 000544 ¥7.15 ¥7.36 +3% vs BACTIQ
Fujian Longking Co 600388 ¥17.47 ¥12.37 −29% vs BACTIQ
Veralto Corporation VLTO $117.09 $69.81 −40% vs BACTIQ
Munters Group MTRS kr 128.95 kr 48.58 −62% vs BACTIQ
GVS S.p.A GVS €5.84 €1.74 −70% vs BACTIQ
CECO Environmental Corp CECO $43.71 $10.47 −76% vs BACTIQ

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bactiquant AS: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bactiquant AS Fair Value". https://www.fairvalue-calculator.com/stock/BACTIQ

Frequently asked questions

Is Bactiquant AS (BACTIQ) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of kr 0.2890 versus a price of kr 2.99, about 90% lower (overvalued).
What is the fair value of BACTIQ?
Our model-based fair value for Bactiquant AS is kr 0.2890 (as of Nov 4, 2026), built from audited fundamentals. The current price: kr 2.99.
What is the quality score of BACTIQ?
Bactiquant AS has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bactiquant AS (BACTIQ)?
Our model-based price target is the fair value of kr 0.2890 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario kr 0.1870, optimistic scenario kr 0.3570. It is a calculation from audited fundamentals, not an analyst target.
What is the Bactiquant AS stock forecast for 2026?
Our models put fair value at kr 0.2890, about 90% lower versus a price of kr 2.99 (overvalued). Cautious scenario kr 0.1870, optimistic scenario kr 0.3570. The calculation is refreshed regularly with new filings.
What is the revenue of Bactiquant AS (BACTIQ)?
Bactiquant AS reported trailing-twelve-month revenue of about 9.5M DKK (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Bactiquant AS (BACTIQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bactiquant AS it is kr 0.2890 per share (as of Nov 4, 2026), against a price of kr 2.99. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Bactiquant AS stock overvalued or undervalued in 2026?
As of Nov 4, 2026, BACTIQ trades above its calculated fair value: price kr 2.99, fair value kr 0.2890, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BACTIQ?
No. The price is what the market pays today (kr 2.99); the fair value is what the company's own numbers justify (kr 0.2890). For Bactiquant AS the two are kr 2.70 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bactiquant AS worth?
The market values Bactiquant AS at about 112M DKK (market capitalisation, as of Nov 4, 2026). Per share that is kr 2.99; our models calculate a fair value of kr 0.2890 per share.
What do the bullish and bearish scenarios say about BACTIQ?
Our models span a range for Bactiquant AS: cautious scenario kr 0.1870, base kr 0.2890, optimistic kr 0.3570 per share (as of Nov 4, 2026, price kr 2.99). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bactiquant AS (BACTIQ)?
Balance-sheet figures for Bactiquant AS (as of Nov 4, 2026): return on equity −114.0%, debt of 0.39 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is BACTIQ from its 52-week high?
Bactiquant AS trades at kr 2.99, about 24% below its 52-week high of kr 3.95 and 46% above the low of kr 2.05 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.2890 is for.
Which stocks are comparable to Bactiquant AS?
From the same area (Industrials) we also value Veralto Corporation, Zurn Elkay Water Solutions Corporation, Fujian Longking Co, Munters Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bactiquant AS stock attractive at the current price?
The data as of Nov 4, 2026: price kr 2.99, calculated fair value kr 0.2890 (−90%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BACTIQ calculated?
We run Bactiquant AS through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of kr 0.2890 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bactiquant AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bactiquant AS (BACTIQ)?
The closing price on Nov 6, 2026 was kr 2.99. Our model-based fair value is kr 0.2890, about 90% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bactiquant AS right now?
The price sits above even our optimistic bull case (kr 0.3570). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.1870 to kr 0.3570) leaves room in how you read the outcome.

Key figures of Bactiquant AS

How large is the market capitalisation of Bactiquant AS (BACTIQ)?
The market capitalisation of Bactiquant AS is 112M DKK (≈ $16.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bactiquant AS (BACTIQ)?
The price-to-sales ratio of Bactiquant AS is 9.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bactiquant AS (BACTIQ)?
Earnings per share at Bactiquant AS are kr −0.3400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bactiquant AS (BACTIQ)?
The net margin of Bactiquant AS is −122% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bactiquant AS (BACTIQ)?
The return on equity (ROE) of Bactiquant AS is −114% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bactiquant AS (BACTIQ)?
On an EBIT basis the return on assets of Bactiquant AS is −56.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bactiquant AS (BACTIQ)?
The operating margin of Bactiquant AS is −83.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bactiquant AS (BACTIQ)?
Revenue at Bactiquant AS is growing +29.5% versus a year earlier (3y avg −12.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Bactiquant AS (BACTIQ) generate?
The free cash flow of Bactiquant AS is −10.5M DKK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Bactiquant AS (BACTIQ) hold?
Bactiquant AS holds more cash than debt, 9.6M DKK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Bactiquant AS in the live analysis

One click puts Bactiquant AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.